Stifel lowered the firm’s price target on Insulet (PODD) to $350 from $370 and keeps a Buy rating on the shares as part of the firm’s 2026 overview note for the dental, diabetes, and aesthetics sectors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet Extends Key Supply Agreement with NXP USA
- Insulet’s Omnipod M Study Completes Key Milestone in Type 2 Diabetes Onboarding
- Target upgraded, Stryker downgraded: Wall Street’s top analyst calls
- Insulet assumed at Hold from Buy at TD Cowen
- Balanced Risk–Reward for Insulet: Strong Growth but Rising Competition Justifies Hold Rating and $294 Target